Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions

BACKGROUND: Erythropoietin (EPO) provides an alternative to transfusion for increasing red blood cell mass and treating anemia in cancer patients. However, recent studies have reported increased adverse events and/or reduced survival in patients receiving both EPO and chemotherapy, potentially relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyake, Makito, Goodison, Steve, Lawton, Adrienne, Zhang, Ge, Gomes-Giacoia, Evan, Rosser, Charles J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844377/
https://www.ncbi.nlm.nih.gov/pubmed/24004818
http://dx.doi.org/10.1186/1756-8722-6-65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844377/
https://www.ncbi.nlm.nih.gov/pubmed/24004818
http://dx.doi.org/10.1186/1756-8722-6-65

Ejemplares similares